1233 GMT - Sanofi's portfolio awaits proof of improvement as the French drugmaker seeks a research-and-development turnaround to drive a pipeline renaissance, Berenberg's Luisa Hector and Kerry Holford say in a research note. The market reaction to Friday's update from Sanofi and partner Regeneron on experimental respiratory drug itepekimab looks overdone, according to Berenberg. Moreover, Sanofi's pipeline renaissance is driven by a shift toward wholly-owned assets and itepekimab is shared with Regeneron, the analysts say. "While the jury remains out on Sanofi's improving R&D profile, we remain of the view that zero value is assigned to pipeline in Sanofi's share price," the analysts say. Berenberg cuts its target price on Sanofi to 118 euros from 120 euros. Shares fall 1.8% to 85.93 euros. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 02, 2025 08:33 ET (12:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。